Evidence map›Paper›PMID 33236327›Full record

ReviewMolecular neurobiology2021

Long Non-coding RNAs as Promising Therapeutic Approach in Ischemic Stroke: a Comprehensive Review.

Marta Wolska, Joanna Jarosz-Popek, Eva Junger, Zofia Wicik, Tahmina Porshoor, Lucia Sharif, Pamela Czajka, Marek Postula, Dagmara Mirowska-Guzel, Anna Czlonkowska and 1 more

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Molecular neurobiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
4.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 2 countries.

Marta WolskaDepartment of Experimental and Clinical Pharmacology, Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Banacha 1B str., Warsaw, 02-097, Warsaw, Poland.ORCID https://orcid.org/0000-0002-3190-8113
Joanna Jarosz-PopekDepartment of Experimental and Clinical Pharmacology, Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Banacha 1B str., Warsaw, 02-097, Warsaw, Poland.ORCID https://orcid.org/0000-0003-0960-0208
Eva JungerDepartment of Experimental and Clinical Pharmacology, Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Banacha 1B str., Warsaw, 02-097, Warsaw, Poland.ORCID https://orcid.org/0000-0002-9894-6237
Zofia WicikDepartment of Experimental and Clinical Pharmacology, Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Banacha 1B str., Warsaw, 02-097, Warsaw, Poland.ORCID https://orcid.org/0000-0002-2857-1986
Tahmina PorshoorDepartment of Experimental and Clinical Pharmacology, Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Banacha 1B str., Warsaw, 02-097, Warsaw, Poland.ORCID https://orcid.org/0000-0002-8810-6867
Lucia SharifDepartment of Experimental and Clinical Pharmacology, Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Banacha 1B str., Warsaw, 02-097, Warsaw, Poland.ORCID https://orcid.org/0000-0002-6093-1857
Pamela CzajkaDepartment of Experimental and Clinical Pharmacology, Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Banacha 1B str., Warsaw, 02-097, Warsaw, Poland.ORCID https://orcid.org/0000-0002-0193-0192
Marek PostulaDepartment of Experimental and Clinical Pharmacology, Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Banacha 1B str., Warsaw, 02-097, Warsaw, Poland.ORCID https://orcid.org/0000-0002-7826-4458
Dagmara Mirowska-GuzelDepartment of Experimental and Clinical Pharmacology, Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Banacha 1B str., Warsaw, 02-097, Warsaw, Poland.ORCID https://orcid.org/0000-0001-6294-3256
Anna CzlonkowskaDepartment of Experimental and Clinical Pharmacology, Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Banacha 1B str., Warsaw, 02-097, Warsaw, Poland.ORCID https://orcid.org/0000-0002-1956-1866
Ceren EyiletenDepartment of Experimental and Clinical Pharmacology, Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, Banacha 1B str., Warsaw, 02-097, Warsaw, Poland. ceyileten@wum.edu.pl.ORCID https://orcid.org/0000-0002-3324-9625
Medical University of Warsaw · PL

Funding

2017/25/N/NZ5/00545 2017/25/N/NZ5/005452018/31/B/NZ7/01137 2018/31/B/NZ7/01137
6 · The paper itself

Abstract

In recent years, ischemic stroke (IS) has been one of the major causes of disability and mortality worldwide. The general mechanism of IS is based on reduced blood supply to neuronal tissue, resulting in neuronal cell damage by various pathological reactions. One of the main techniques for acute IS treatment entails advanced surgical approaches for restoration of cerebral blood supply but this is often associated with secondary brain injury, also known as ischemic reperfusion injury (I/R injury). Many researches have come to emphasize the significant role of long non-coding RNAs (lncRNAs) in IS, especially in I/R injury and their potential as therapeutic approaches. LncRNAs are non-protein transcripts that are able to regulate cellular processes and gene expression. Further, lncRNAs have been shown to be involved in neuronal signaling pathways. Several lncRNAs are recognized as key factors in the physiological and pathological processes of IS. In this review, we discuss the role of lncRNAs in neuronal injury mechanisms and their association with brain neuroprotection. Moreover, we identify the lncRNAs that show the greatest potential as novel therapeutic approaches in IS, which therefore merit further investigation in preclinical research. Graphical Abstract.

Indexed as

AnimalsCell DeathHumansIschemic StrokeNerve DegenerationNeuronsRNA, Long NoncodingSignal TransductionRNA, Long NoncodingIschemia/reperfusionlncRNANon-coding RNANovel therapyStrokeTherapeutic approachTreatment

Identifiers

PMID33236327
PMCPMC7932985
OpenAlexW3110254412

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.